A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Inclusion Criteria:

• Histological or cytological diagnosis of advanced, unresectable, and/or metastaticor relapsed/refractory solid tumor.

ECOG PS 0 or 1

• Presence of at least 1 measurable lesion based on RECIST version 1.1 that has notbeen previously irradiated.

• Documentation of mutated KRAS gene

1. PDAC, CRC, Other tumor types: Confirmed KRAS mutation, any variant

2. NSCLC: Confirmed KRAS mutation, any variant except previously treated G12C. Ifdriver mutation, must have failed precision medicine therapy [eg, inhibitors ofepidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK),c-ros oncogene 1 (ROS1), and others].

• Part 1 and Part 2a: Participant must have progressed on standard treatment(s) forwhich no additional, effective therapy is available.

1. PDAC (2-3L): Participants must have received and radiologically progressed onprior lines of systemic therapy for metastatic pancreatic adenocarcinoma. Ifparticipants received prior neoadjuvant or adjuvant chemotherapy and progressedwithin 6 months of the last dose, then this should be considered as a priorline of systemic therapy.

2. NSCLC (2-3L): Participants must have received prior lines of anti-cancertreatment and progressed on at least a platinum-containing chemotherapy regimenand checkpoint inhibitor therapy; for participants with EGFR, ALK, or othergenomic tumor alterations, participants must have progressed on approvedtherapy for these alterations.

3. CRC (2-3L): Participants must have had one or two prior systemic treatmentregimens for mCRC. For either one or two prior treatments, these regimens musthave included a fluoropyrimidine, oxaliplatin, or irinotecan; for one priortreatment, exposure to VEGF/VEGF receptor (VEGFR) inhibitor is optional;

4. Other tumors: Participants, in the judgment of the investigator, must haveprogressed or become intolerant to all available standard therapies, or haverefused such therapy.

• Part 2b:

1. PDAC (1L) Cohort A2: Participants must not have received prior chemotherapy formetastatic disease. Participant could have received neoadjuvant therapy,adjuvant therapy, or adjuvant chemo-radiotherapy, as long as relapse did notoccur within 6 months of completing these forms of adjuvant treatment. If so,the relapse within 6 months would be considered a line of therapy; theparticipant would be considered 2L, and not 1L.

2. CRC (2-3L) Cohort B2: Participants must have had one or two prior systemictreatment regimens for mCRC. For either one or two prior treatments, theseregimens must have included a fluoropyrimidine, irinotecan, oxaliplatin; forone prior treatment, exposure to a VEGF/VEGF receptor (VEGFR) inhibitor isoptional.

3. CRC (1L) Cohort B3: Participants must not have had prior chemotherapy foradvanced or metastatic disease. Participant could have received adjuvantchemotherapy or adjuvant chemo-radiotherapy, as long as relapse did not occurwithin 6 months of complete of adjuvant therapy. If so, the relapse within 6months would be considered a line of therapy; the participant would beconsidered 2L, and not 1L.

4. NSCLC (1L) Cohort C2: Participants must have a TPS ≥50% and must not havereceived prior systemic treatment setting.

5. NSCLC (1L) Cohort C3: Participants with any TPS and must not have receivedprior systemic treatment setting.

Exclusion Criteria:

• Active or history of pneumonitis/ILD, pulmonary fibrosis requiring treatment withsystemic steroid therapy, including evidence to suggest pneumonitis/ILD on baselineassessments including imaging.

• Diagnosis of immunodeficiency or an active autoimmune disease that require systemictreatment with chronic systemic steroid therapy (in dosing exceeding 10 mg daily ofprednisone equivalent) or any other form of immunosuppressive therapy in the past 2years.

• Sensory peripheral neuropathy ≥Grade 2

• Active or history of clinically significant gastrointestinal (GI) disease (includingbut not limited to inflammatory GI disease [eg, ulcerative colitis, Crohn's disease,inflammatory bowel disease], immune-mediated colitis, peptic ulcer disease, GIbleeding, chronic diarrhea) and other conditions that are unresolved and/or mayincrease the risk associated with study participation or study treatmentadministration.

• Active bleeding disorder, including GI bleeding, as evidenced by hematemesis,significant hemoptysis or melena in the past 6 months.

• Major surgery or completion of radiation therapy ≤4 weeks prior toenrollment/randomization or radiation therapy that included >30% of the bone marrow.

• Known sensitivity or contraindication to any component of study intervention (PF 07934040, gemcitabine, nab-paclitaxel, cetuximab, bevacizumab, FOLFOX, 5-FU,pembrolizumab, cisplatin, carboplatin, pemetrexed, SHP2 inhibitor(s),cyclin-dependent kinase (CDK) inhibitor(s), antibody drug conjugates (ADCs) or EGFRinhibitor(s)).

• Hematologic abnormalities.

• Renal impairment.

• Hepatic abnormalities.